A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Running, not enrolling · Phase 3

Conditions studied: Wet Age Related Macular Degeneration, wAMD

In brief

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Key facts

Study ID
NCT06683742
Run by
EyePoint Pharmaceuticals, Inc.
People needed
400
Starts
2024-11-27
Expected to finish
2027-10-01
Last updated by the study team
2026-08-04

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.